$TAK

Greenway Nicola Deidre Petal sold $606K of TAK

Greenway Nicola Deidre Petal (Chief Human Resources Officer) sold 34,603 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at an average of $17.51 ($17.50–$17.51, $0.61M total) across 2 trades on 2026-08-10.

Original reporting
SEC EDGAR · Greenway Nicola Deidre Petal
Published Aug 12, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TAK
Neutral
medium confidence
Mentioned
$TAK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale amount, price range, and post-transaction holdings; it may slightly influence short-term sentiment but does not constitute new company guidance or events.

02

Market read

A routine insider sale by a senior executive is disclosed, with no accompanying fundamental catalyst in the text.

03

What to watch

The article does not provide context on total compensation, prior sale history, or whether other insiders sold/bought around the same time, limiting inference.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12, transaction dated 2026-08-10

Background

The article is a SEC Form 4 insider transaction disclosure for Takeda, reported via SEC EDGAR.

Company-level read

Ticker impact

$TAKNeutralMedium confidence
Context

Takeda (TAK) is the Form 4 issuer, showing CFO Greenway Nicola Deidre Petal sold 34,603 shares at about $17.51 on 2026-08-10.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless accompanied by other disclosures.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan stated and no accompanying company-specific operational or financial update in the text.

Market effects

Insider selling in large pharma is usually not sector-moving absent broader guidance or regulatory/clinical catalysts.

None indicated.

None indicated.

Counterpoint

The sale could be driven by diversification, taxes, or pre-planned liquidity needs rather than a negative view on Takeda’s prospects.

Key entities

  • Takeda Pharmaceutical Co Ltd

    Subject of the Form 4 insider transaction disclosure.

  • Greenway Nicola Deidre Petal

    Chief Human Resources Officer who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AZNMedAI 8/10

AstraZeneca: Stomach Cancer Drug With $3 to $5 Billion Sales Potential, and One Significant Wrinkle

AstraZeneca (AZN) reported that its drug sone-ve doubled median survival in stomach cancer patients who had already tried at least two treatments, with median survival rising from 5.0 to 10.0 months. The company expects peak annual sales of $3B to $5B. Takeda (TAK) also reported positive results for its rival drug, arcotatug tavatecan, meeting both primary endpoints.

$TAKHighAI 9/10

Takeda reports positive phase 3 trial results for gastric cancer drug

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

$TAKLowAI 8/10

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Takeda's VERDICT trial showed that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance (vs. symptomatic remission) prolonged time to complications by 70%. The study met its primary endpoint, with Group 3 (disease clearance) showing longer time to complications (HR 0.33, P=0.0014). Over 50% of patients in Group 3 achieved their target by Week 16. The trial also identified molecular patterns associated with early disease clearance.